Tango Therapeutics, Inc. (NASDAQ: TNGX) reported Q4 EPS of ($0.29), $0.03 better than the analyst estimate of ($0.32). Revenue for the quarter came in at $0 versus the consensus estimate of $500.4 thousand.

For earnings history and earnings-related data on Tango Therapeutics, Inc. (TNGX) click here.